Stock Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Announces Appointment of Mark J. Casey as General Counsel and Secretary of the Board of Directors

Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, announced that it has appointed Mark J. Caseyas Senior Vice President, General Counsel and Secretary of the Board of Directors.

Vincent J. Milano, Chief Executive Officer of Idera Pharmaceuticals stated, “Mark’s experience and acumen are perfect matches for Idera and we look forward to the immediate positive impact he will make to our growing team. Importantly, Mark fits incredibly well into the corporate culture we are fostering at Idera that will continue to drive us to delivering therapies for patients suffering from life-threatening diseases whose needs are currently unmet.”

“I am thrilled to be joining the team at Idera,” stated Mark Casey, Idera’s General Counsel. “The company’s incredible focus on developing targeted therapies for rare diseases and cancers is critically important to patients and I am very passionate about doing my part to contribute to the Idera team’s mission.”

Mr. Casey most recently served as Chief Administrative Officer, Senior Vice President, General Counsel and Secretary of Hologic Incorporated. Prior toHologic, Mr. Casey, held roles of increasing responsibility at Cytyc Corporationand Boston Scientific Corporation. Mr. Casey received his J.D. from Suffolk University Law School and his Bachelor of Science from Syracuse University. (Original Source)

Shares of Idera Pharmaceuticals closed last Friday at $3.56 . IDRA has a 1-year high of $5.48 and a 1-year low of $1.94. The stock’s 50-day moving average is $3.42 and its 200-day moving average is $3.94.

On the ratings front, Idera Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on June 15, J.P. Morgan analyst Anupam Rama initiated coverage with a Buy rating on IDRA and a price target of $6, which implies an upside of 68.5% from current levels. Separately, on June 10, Cowen’s Boris Peaker maintained a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Anupam Rama and Boris Peaker have a total average return of 88.3% and 35.0% respectively. Rama has a success rate of 71.4% and is ranked #314 out of 3681 analysts, while Peaker has a success rate of 59.1% and is ranked #37.

Idera Pharmaceuticals Inc is a clinical stage biotechnology company.The Company is engaged in the discovery, development and commercialization of novel therapeutics for oncology and rare diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts